American Oriental Bioengineering Announces Change in Independent Auditor
August 11 2009 - 8:30AM
PR Newswire (US)
NEW YORK, Aug. 11 /PRNewswire-Asia-FirstCall/ -- American Oriental
Bioengineering, Inc. (NYSE:AOB), ("the Company" or "AOBO"), a
pharmaceutical company dedicated to improving health through the
development, manufacture and commercialization of a broad range of
prescription and over the counter ("OTC") products in China,
announced today that the Audit Committee of the Board of Directors
of AOBO approved the engagement of Ernst & Young Hua Ming
("EY") as the Company's independent registered public accounting
firm for the year ending December 31, 2009. During the years ended
December 31, 2007 and 2008 and through August 10, 2009, there were
no disagreements with the Company's prior independent auditor,
Weinberg & Company, P.A., on any matter of accounting
principles or practices, financial statement disclosure, or
auditing scope or procedure, which disagreements, if not resolved
to the satisfaction of Weinberg, would have caused Weinberg to make
reference to the subject matter of the disagreements in its reports
on the consolidated financial statements for such years. About
American Oriental Bioengineering, Inc. American Oriental
Bioengineering, Inc. is a pharmaceutical company dedicated to
improving health through the development, manufacture and
commercialization of a broad range of prescription and over the
counter products in China. DATASOURCE: American Oriental
Bioengineering, Inc. CONTACT: Ashley M. Ammon of Integrated
Corporate Relations, Inc., +1-203-682-8200
Copyright
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024